Fig. 1 |. B cells present t-mOVA to CD4⁺ T cells, which leads to impaired CD4⁺ T-cell priming and suppressed responses to c-OVA.

a–e, Proliferation index (a), fold expansion (b), activation marker expression (c), IFNγ production (d) and representative flow plots (e) of carboxyfluorescein diacetate succinimidyl ester (CFSE)-labelled OT-II cells 6 days after transfer on embryonic day (E) 12.5–E15.5 into WT females mated as indicated. Some groups received intravenous injections of adjuvants (Adj; comprised of poly(I:C) and anti-CD40 antibodies) with or without c-OVA at the time of OT-II transfer. Adjusted P values were determined by ordinary one-way analysis of variance (ANOVA) with Sidak’s multiple comparisons test. Each group was compared to the xB6 control group, and the xB6 + c-OVA/Adj group was compared to the xmOVA + c-OVA/Adj group. NS, not significant. Bars show mean ± s.d. Data were accumulated over 11 independent experiments and all mice are displayed. f, Representative CFSE dilution profiles (n ≥ 6 per group) indicating the extent of OT-II (top row) and OT-I (bottom row) cell proliferation 50 h after late-gestational transfer into xmOVA pregnant mice of the indicated genotypes. See Extended Data Fig. 3b, c for summary data.